EP2751083A4 - Chinolonverbindung - Google Patents

Chinolonverbindung

Info

Publication number
EP2751083A4
EP2751083A4 EP12827305.9A EP12827305A EP2751083A4 EP 2751083 A4 EP2751083 A4 EP 2751083A4 EP 12827305 A EP12827305 A EP 12827305A EP 2751083 A4 EP2751083 A4 EP 2751083A4
Authority
EP
European Patent Office
Prior art keywords
quinolone compound
quinolone
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12827305.9A
Other languages
English (en)
French (fr)
Other versions
EP2751083B1 (de
EP2751083A1 (de
Inventor
Mamuti Abudusaimi
Fangguo Ye
Jiangqin Sun
Hisashi Miyamoto
Jay-Fei Cheng
Daisuke Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to SI201231233T priority Critical patent/SI2751083T1/en
Priority to PL12827305T priority patent/PL2751083T3/pl
Priority to EP17202139.6A priority patent/EP3318557A3/de
Publication of EP2751083A1 publication Critical patent/EP2751083A1/de
Publication of EP2751083A4 publication Critical patent/EP2751083A4/de
Application granted granted Critical
Publication of EP2751083B1 publication Critical patent/EP2751083B1/de
Priority to HRP20180483TT priority patent/HRP20180483T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP12827305.9A 2011-08-31 2012-08-30 Chinolonverbindung Active EP2751083B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI201231233T SI2751083T1 (en) 2011-08-31 2012-08-30 Quinolone compound
PL12827305T PL2751083T3 (pl) 2011-08-31 2012-08-30 Związek chinolonowy
EP17202139.6A EP3318557A3 (de) 2011-08-31 2012-08-30 Chinolonverbindung
HRP20180483TT HRP20180483T1 (hr) 2011-08-31 2018-03-22 Spoj kinolona

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011001477 2011-08-31
CN2012001044 2012-08-06
PCT/CN2012/080753 WO2013029548A1 (en) 2011-08-31 2012-08-30 Quinolone compound

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP17202139.6A Division EP3318557A3 (de) 2011-08-31 2012-08-30 Chinolonverbindung
EP17202139.6A Division-Into EP3318557A3 (de) 2011-08-31 2012-08-30 Chinolonverbindung

Publications (3)

Publication Number Publication Date
EP2751083A1 EP2751083A1 (de) 2014-07-09
EP2751083A4 true EP2751083A4 (de) 2015-06-10
EP2751083B1 EP2751083B1 (de) 2017-12-27

Family

ID=47755336

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17202139.6A Withdrawn EP3318557A3 (de) 2011-08-31 2012-08-30 Chinolonverbindung
EP12827305.9A Active EP2751083B1 (de) 2011-08-31 2012-08-30 Chinolonverbindung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP17202139.6A Withdrawn EP3318557A3 (de) 2011-08-31 2012-08-30 Chinolonverbindung

Country Status (29)

Country Link
US (7) US9067887B2 (de)
EP (2) EP3318557A3 (de)
JP (4) JP6106174B2 (de)
KR (3) KR101996697B1 (de)
CN (3) CN105712976A (de)
AR (1) AR087747A1 (de)
AU (2) AU2012303954B2 (de)
BR (1) BR112014000665B8 (de)
CA (1) CA2845459C (de)
CO (1) CO6920292A2 (de)
CY (1) CY1120066T1 (de)
DK (1) DK2751083T3 (de)
EA (2) EA030867B1 (de)
ES (1) ES2660973T3 (de)
HK (4) HK1198828A1 (de)
HR (1) HRP20180483T1 (de)
HU (1) HUE036301T2 (de)
IL (1) IL230559B (de)
LT (1) LT2751083T (de)
MX (2) MX371361B (de)
MY (1) MY165004A (de)
NO (1) NO2751083T3 (de)
PL (1) PL2751083T3 (de)
PT (1) PT2751083T (de)
SG (3) SG10201505811QA (de)
SI (1) SI2751083T1 (de)
TW (3) TWI583680B (de)
WO (1) WO2013029548A1 (de)
ZA (1) ZA201402326B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670410B1 (de) * 2011-02-01 2017-12-20 Emergent Product Development Gaithersburg Inc. Antimikrobielle 4-oxochinolizine
CN105712976A (zh) * 2011-08-31 2016-06-29 大塚制药株式会社 喹诺酮化合物
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
AR096135A1 (es) 2013-05-02 2015-12-09 Actelion Pharmaceuticals Ltd Derivados de la quinolona
JP2016523964A (ja) 2013-07-08 2016-08-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔタンパク質阻害剤としての三環式複素環
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
LT3134403T (lt) 2014-04-23 2020-05-11 Incyte Corporation 1h-pirolo[2,3-c]piridin-7(6h)-onai ir pirazolo[3,4-c]piridin-7(6h)-onai, kaip bet baltymų inhibitoriai
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10314820B2 (en) 2014-12-04 2019-06-11 Procomcure Biotech Gmbh Imidazole-based heterocyclic compounds
LT3226858T (lt) 2014-12-04 2021-06-10 Procomcure Biotech Gmbh Imidazolo pagrindo antimikrobiniai agentai
BR112018001441A2 (pt) * 2015-07-28 2018-09-11 Vyome Biosciences Pvt Ltd antibacterianos terapêuticos e profiláticos
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017117355A1 (en) * 2015-12-29 2017-07-06 ImmuneTarget, Inc. 2h-chromeno[2,3-d]pyrimidine-2,4(3h)-diones as nf-kb inhibitors
EP3472157B1 (de) 2016-06-20 2023-04-12 Incyte Corporation Kristalline feste formen eines bet-inhibitors
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
KR102537749B1 (ko) 2017-06-14 2023-05-26 산요 시키소 가부시키가이샤 안료 분산체 및 그것을 포함하는 착색 조성물
CN107964020B (zh) * 2018-01-11 2019-07-05 河南大学 1-(n-左氧氟沙星酰胺基)-6-氟-7-哌嗪萘啶酮酸化合物及其制备方法和应用
CN108191889B (zh) * 2018-01-11 2019-06-07 河南大学 1-(n-氧氟沙星酰胺基)-6-氟-7-哌嗪萘啶酮酸化合物及其制备方法和应用
US20210317111A1 (en) 2018-08-13 2021-10-14 Otsuka Pharmaceutical Co., Ltd. Novel medicament for treating inflammatory bowel disease
CA3128947A1 (en) * 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
CN110551124B (zh) * 2019-06-14 2021-01-08 山东省联合农药工业有限公司 一种喹诺酮类化合物或其农药学上可接受的盐及其制备方法与用途
CN112624970B (zh) * 2019-09-24 2022-10-28 南开大学 8位芳基取代喹啉氮氧化物在抗植物病毒及杀菌方面的应用
CN110724097B (zh) * 2019-11-11 2021-03-09 山东畜牧兽医职业学院 一种治疗耐药性微生物菌的化合物及其制备方法
JP2023012557A (ja) 2020-02-10 2023-01-26 大塚製薬株式会社 新規肝性脳症治療剤
JP2023012559A (ja) 2020-02-10 2023-01-26 大塚製薬株式会社 新規炎症性疾患治療剤
JP2023012558A (ja) 2020-02-10 2023-01-26 大塚製薬株式会社 腸内細菌叢構成比率調整剤
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023208172A1 (en) * 2022-04-29 2023-11-02 Beigene , Ltd. Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors
WO2024012421A1 (en) * 2022-07-11 2024-01-18 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compositions comprising a quinolone compound for irritable bowel syndrome
WO2024128235A1 (ja) * 2022-12-13 2024-06-20 大塚製薬株式会社 キノロン化合物の製造方法
WO2024138292A1 (zh) * 2022-12-26 2024-07-04 深圳阿尔法分子科技有限责任公司 一种新型具有抗菌和抗癌功能的苯基喹诺酮类化合物及其制备
CN118255716A (zh) * 2022-12-26 2024-06-28 深圳阿尔法分子科技有限责任公司 一种新型具有抗菌和抗癌功能的苯基喹诺酮类化合物及其制备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046223A1 (fr) * 1999-02-05 2000-08-10 Toyama Chemical Co., Ltd. Derives tricycliques d'acide quinolonecarboxylique ou sels de ces derives
WO2002009758A2 (en) * 2000-08-01 2002-02-07 Wockhardt Limited Inhibitors of cellular efflux pumps of microbes
US20090247578A1 (en) * 2006-11-10 2009-10-01 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
EP2177214A1 (de) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Feste orale Dosierungsformen und Verwendungen

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5781486A (en) * 1980-11-10 1982-05-21 Otsuka Pharmaceut Co Ltd Benzo(ij)quinolidine-2-carboxylic acid derivative
JPS5872589A (ja) * 1981-10-28 1983-04-30 Dai Ichi Seiyaku Co Ltd ピリド〔１，２，３−ｄｅ〕〔１，４〕ベンゾオキサジン誘導体
US4443447A (en) * 1982-10-25 1984-04-17 Riker Laboratories, Inc. Phenyl-substituted tricyclic antibacterial agents
US4623650A (en) * 1984-12-06 1986-11-18 Pfizer Inc. Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids
US4636506A (en) * 1984-12-06 1987-01-13 Pfizer, Inc. 7-heterocyclic-1,4-dihydroquinolones
ZA859283B (en) 1984-12-06 1987-07-29 Pfizer Substituted dihydroquinolone carboxylic acids and anti-bacterial compositions containing them
US4797490A (en) * 1984-12-06 1989-01-10 Pfizer Inc. Process for the preparation of 3-(2'-fluorophenyl)pyridine
JPS62228063A (ja) * 1985-12-27 1987-10-06 Sankyo Co Ltd キノリンカルボン酸誘導体
IT1197841B (it) * 1986-10-14 1988-12-06 Mediolanum Farmaceutici Srl Derivati pirido-benzotiazinici ad attivita' antibatterica ed a lunga durata di azione
US4929613A (en) 1987-08-26 1990-05-29 Warner-Lambert Company Antibacterial agents
US5081254A (en) 1987-08-26 1992-01-14 Warner-Lambert Company Antibacterial agents
US5075319A (en) * 1987-09-08 1991-12-24 Sterling Drug Inc. Pyridinyl-quinolone compounds, their preparation and use
US4839355A (en) * 1987-09-09 1989-06-13 Sterling Drug Inc. Tricyclic-pyridinylquinoline compounds, their preparation and use
WO1989005643A1 (en) * 1987-12-18 1989-06-29 Pfizer Inc. Heterocyclic-substituted quinoline-carboxylic acids
DE3816119A1 (de) * 1988-05-11 1989-11-23 Bayer Ag 7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
JPH0366301A (ja) 1989-08-03 1991-03-22 Asahi Corp 靴底射出成形金型
KR910009333B1 (ko) * 1989-10-23 1991-11-11 재단법인 한국화학연구소 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법
JP2613139B2 (ja) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 キノロンカルボン酸誘導体
US5308843A (en) * 1990-09-11 1994-05-03 Sterling Drug Inc. Method of inhibiting mammalian topoisomerase II and malignant cell growth in mammals, with substituted (S)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4 ]-benzoxazine(and-benzothiazine)-6-carboxylic acids
DE69132314T2 (de) 1990-12-05 2000-12-14 Naeja Pharmaceutical Inc., Edmonton 7-substituierte-6-fluor-1,4-dihydro-4-oxo-chinolin-3-carbonsäurederivate als antibakterielle wirkstoffe
WO1996005192A1 (fr) 1994-08-12 1996-02-22 Toyama Chemical Co., Ltd. Derive du nouvel acide quinolone- ou naphthyridonecarboxylique ou son sel
EP0994878B1 (de) 1997-06-26 2001-11-28 Dong Wha Pharmaceutical Industrial Co. Ltd. Derivate der chinoloncarbonsäure
WO1999003465A1 (fr) 1997-07-16 1999-01-28 Eisai Co., Ltd. Antibiotiques contenant des derives indole
JP4370002B2 (ja) * 1997-08-08 2009-11-25 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
US6337399B1 (en) 1997-10-27 2002-01-08 Toyama Chemical Co., Ltd. Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates therefor, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient
JP3346766B2 (ja) * 1998-04-06 2002-11-18 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
JP2000229946A (ja) * 1998-12-10 2000-08-22 Toyama Chem Co Ltd キノロンカルボン酸の製造法およびその中間体
US20020049223A1 (en) * 1999-11-05 2002-04-25 Elmore Steven W. Quinoline and naphthyridine carboxylic acid antibacterials
DE10026903A1 (de) * 2000-06-03 2002-01-10 Cpc Cellular Process Chemistry Verfahren zur Herstellung von Chinolon-3-carbonsäuren
JP2003104988A (ja) * 2001-09-28 2003-04-09 Sato Pharmaceutical Co Ltd 抗菌剤として有用なキノロン誘導体
US7012144B2 (en) 2001-12-31 2006-03-14 Korea Research Institute Of Chemical Technology Quinolone carboxylic acid derivatives
JP3885679B2 (ja) * 2002-06-28 2007-02-21 株式会社日立製作所 電子機器
US20070224282A1 (en) * 2005-03-28 2007-09-27 Toyama Chemical Co., Ltd. Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
EP1992690B1 (de) * 2006-02-17 2014-05-21 Morinaga Milk Industry Co., Ltd. Verfahren und kit zum nachweis eines mikroorganismus
CN101168541A (zh) * 2006-10-26 2008-04-30 孙飘扬 喹诺酮羧酸类衍生物及其制备方法和药物用途
US20090270379A1 (en) * 2008-04-23 2009-10-29 Macielag Mark J Quinolone derivatives useful as antibacterial agents
CN105712976A (zh) * 2011-08-31 2016-06-29 大塚制药株式会社 喹诺酮化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046223A1 (fr) * 1999-02-05 2000-08-10 Toyama Chemical Co., Ltd. Derives tricycliques d'acide quinolonecarboxylique ou sels de ces derives
WO2002009758A2 (en) * 2000-08-01 2002-02-07 Wockhardt Limited Inhibitors of cellular efflux pumps of microbes
US20090247578A1 (en) * 2006-11-10 2009-10-01 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
EP2177214A1 (de) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Feste orale Dosierungsformen und Verwendungen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FROELICH-AMMON S J ET AL: "NOVEL 1-8-BRIDGED CHIRAL QUINOLONES WITH ACTIVITY AGAINST TOPOISOMERASE II: STEREOSPECIFICITY OF THE EUKARYOTIC ENZYME", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 37, no. 4, 1 April 1993 (1993-04-01), pages 646 - 651, XP002928461, ISSN: 0066-4804 *
MASAHIRO TAKAHATA: "In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 43, no. 5, 1 January 1999 (1999-01-01), pages 1077 - 1084, XP055157504 *
See also references of WO2013029548A1 *
WENTLAND M P ET AL: "Relationship of structure of bridged (2,6-dimethyl-4-pyridinyl)quinolones to mammalian topoisomerase II inhibition", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 3, no. 8, 1 August 1993 (1993-08-01), pages 1711 - 1716, XP026615606, ISSN: 0960-894X, [retrieved on 19930801], DOI: 10.1016/S0960-894X(00)80048-7 *

Also Published As

Publication number Publication date
AU2012303954B2 (en) 2017-06-22
EP3318557A3 (de) 2018-07-11
DK2751083T3 (en) 2018-02-26
KR101996697B1 (ko) 2019-07-04
HK1226077A1 (zh) 2017-09-22
LT2751083T (lt) 2018-03-26
JP2017039733A (ja) 2017-02-23
JP6039025B2 (ja) 2016-12-07
MY165004A (en) 2018-02-28
KR20140087059A (ko) 2014-07-08
US9440951B2 (en) 2016-09-13
EP2751083B1 (de) 2017-12-27
US20200055823A1 (en) 2020-02-20
WO2013029548A1 (en) 2013-03-07
SI2751083T1 (en) 2018-04-30
EA201490530A1 (ru) 2014-06-30
KR101560073B1 (ko) 2015-10-13
CO6920292A2 (es) 2014-04-10
HK1198828A1 (en) 2015-06-12
IL230559A0 (en) 2014-03-31
AR087747A1 (es) 2014-04-16
US20140179675A1 (en) 2014-06-26
SG10201606932TA (en) 2016-10-28
US20150005287A2 (en) 2015-01-01
AU2012303954A1 (en) 2014-02-20
MX2014002338A (es) 2014-03-27
EA034787B1 (ru) 2020-03-20
TWI583680B (zh) 2017-05-21
EP3318557A2 (de) 2018-05-09
EP2751083A1 (de) 2014-07-09
HK1216528A1 (zh) 2016-11-18
AU2017203756A1 (en) 2017-06-22
BR112014000665A2 (pt) 2017-01-10
KR20130095831A (ko) 2013-08-28
HK1252389A1 (zh) 2019-05-24
SG10201505811QA (en) 2015-09-29
TW201319053A (zh) 2013-05-16
JP6106174B2 (ja) 2017-03-29
KR20140139132A (ko) 2014-12-04
CN105017151A (zh) 2015-11-04
TW201718506A (zh) 2017-06-01
US20190077762A1 (en) 2019-03-14
US20170362180A1 (en) 2017-12-21
NO2751083T3 (de) 2018-05-26
JP2018150324A (ja) 2018-09-27
CN103764631B (zh) 2017-02-15
US20210032207A1 (en) 2021-02-04
IL230559B (en) 2019-03-31
AU2017203756B2 (en) 2019-02-07
CY1120066T1 (el) 2018-12-12
EA201890098A3 (ru) 2018-09-28
CN105017151B (zh) 2019-04-02
BR112014000665B1 (pt) 2020-02-18
EA201890098A2 (ru) 2018-05-31
HRP20180483T1 (hr) 2018-05-04
MX371361B (es) 2020-01-27
HUE036301T2 (hu) 2018-06-28
US20160340314A1 (en) 2016-11-24
NZ620447A (en) 2016-02-26
PT2751083T (pt) 2018-03-05
PL2751083T3 (pl) 2018-08-31
TWI606044B (zh) 2017-11-21
CN103764631A (zh) 2014-04-30
ZA201402326B (en) 2016-06-29
ES2660973T3 (es) 2018-03-26
US20150239865A1 (en) 2015-08-27
JP2014525420A (ja) 2014-09-29
TW201630900A (zh) 2016-09-01
BR112014000665B8 (pt) 2020-03-10
MX2019010100A (es) 2019-10-15
CA2845459A1 (en) 2013-03-07
JP2016027046A (ja) 2016-02-18
US9067887B2 (en) 2015-06-30
SG2014004162A (en) 2014-03-28
EA030867B1 (ru) 2018-10-31
CA2845459C (en) 2019-08-27
CN105712976A (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
HK1252389A1 (zh) 喹諾酮化合物
HK1187259A1 (zh) 取代的喹啉化合物
ZA201401553B (en) Cyclopropaneamine compound
EP2842955A4 (de) Trk-hemmende verbindung
GB201106817D0 (en) New compound
ZA201306857B (en) Mesogen-containing compounds
GB201109763D0 (en) Compounds
GB201106395D0 (en) Compounds
GB201107197D0 (en) Compounds
GB201220843D0 (en) Compound
EP2725011A4 (de) Neue verbindung
EP2708540A4 (de) Pyrimidodiazepinonverbindung
GB201122305D0 (en) Novel compound
GB201110938D0 (en) Compounds
GB201105659D0 (en) Compounds
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201112987D0 (en) Novel compound
GB201104669D0 (en) Compound
GB201216448D0 (en) Compound
GB201121538D0 (en) Compound
GB201118102D0 (en) Compound
GB201222716D0 (en) Compound
GB201114195D0 (en) Compounds
GB201111440D0 (en) Compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 215/56 20060101AFI20141210BHEP

Ipc: C07D 471/04 20060101ALI20141210BHEP

Ipc: A61K 31/47 20060101ALI20141210BHEP

Ipc: A61K 31/435 20060101ALI20141210BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150511

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/435 20060101ALI20150505BHEP

Ipc: C07D 215/56 20060101AFI20150505BHEP

Ipc: C07D 471/04 20060101ALI20150505BHEP

Ipc: A61K 31/47 20060101ALI20150505BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198828

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160329

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170707

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YE, FANGGUO

Inventor name: CHENG, JAY-FEI

Inventor name: MIYAMOTO, HISASHI

Inventor name: OKA, DAISUKE

Inventor name: SUN, JIANGQIN

Inventor name: ABUDUSAIMI, MAMUTI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 958161

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012041442

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180221

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2751083

Country of ref document: PT

Date of ref document: 20180305

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180226

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20180483

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2660973

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180326

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20180483

Country of ref document: HR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E015217

Country of ref document: EE

Effective date: 20180321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 26643

Country of ref document: SK

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20171227

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E036301

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400677

Country of ref document: GR

Effective date: 20180627

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198828

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180427

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012041442

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180483

Country of ref document: HR

Payment date: 20190715

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171227

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180483

Country of ref document: HR

Payment date: 20200806

Year of fee payment: 9

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 958161

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171227

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180483

Country of ref document: HR

Payment date: 20210825

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20220629

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180483

Country of ref document: HR

Payment date: 20220823

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20220715

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220830

Year of fee payment: 11

Ref country code: SK

Payment date: 20220713

Year of fee payment: 11

Ref country code: SE

Payment date: 20220714

Year of fee payment: 11

Ref country code: RO

Payment date: 20220720

Year of fee payment: 11

Ref country code: PT

Payment date: 20220824

Year of fee payment: 11

Ref country code: NO

Payment date: 20220809

Year of fee payment: 11

Ref country code: LU

Payment date: 20220816

Year of fee payment: 11

Ref country code: LT

Payment date: 20220809

Year of fee payment: 11

Ref country code: IT

Payment date: 20220712

Year of fee payment: 11

Ref country code: IE

Payment date: 20220712

Year of fee payment: 11

Ref country code: HR

Payment date: 20220823

Year of fee payment: 11

Ref country code: GB

Payment date: 20220707

Year of fee payment: 11

Ref country code: FI

Payment date: 20220809

Year of fee payment: 11

Ref country code: ES

Payment date: 20220901

Year of fee payment: 11

Ref country code: EE

Payment date: 20220721

Year of fee payment: 11

Ref country code: DK

Payment date: 20220809

Year of fee payment: 11

Ref country code: DE

Payment date: 20220621

Year of fee payment: 11

Ref country code: CZ

Payment date: 20220818

Year of fee payment: 11

Ref country code: BG

Payment date: 20220713

Year of fee payment: 11

Ref country code: AT

Payment date: 20220725

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20220719

Year of fee payment: 11

Ref country code: LV

Payment date: 20220706

Year of fee payment: 11

Ref country code: HU

Payment date: 20220717

Year of fee payment: 11

Ref country code: GR

Payment date: 20220720

Year of fee payment: 11

Ref country code: FR

Payment date: 20220709

Year of fee payment: 11

Ref country code: BE

Payment date: 20220718

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220803

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20220705

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20220824

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012041442

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20180483

Country of ref document: HR

Effective date: 20230830

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E015217

Country of ref document: EE

Effective date: 20230831

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20230830

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20230901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240307

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 26643

Country of ref document: SK

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 958161

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240307

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230901

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230901

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20240429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230830

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20241003